Five-year survival for distant-stage prostate cancer improved from 2011 to 2016.
Interview study reveals men’s perception and concerns related to their prostate cancer journey.
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
Maintaining sexual activity in first 6 months after heart attack linked to one-third lower death risk.
Participation rates similar for Black and White patients, treatment and cancer control trials.
And more COVID-19 patients with blood group A or AB require mechanical ventilation, CRRT.
Guidelines recommend participants in late-stage trials be followed for a median of at least 2 months.
Odds of BMD testing up with history of osteoporosis, rheumatoid arthritis, bisphosphonate use.
Venous thromboembolism found in 7.9% of non-ICU patients, 22.7% of ICU patients.
Efforts should be made to address patient concerns about clinical trial participation.